A MULTIPURPOSE AND NOVEL CARRIER FOR DRUG DELIVERY AND TARGETING - VIROSOMES by Kapoor, D et al.
Kapoor et al                                   Journal of Drug Delivery & Therapeutics; 2013, 3(5), 143-147    143 
© 2011, JDDT. All Rights Reserved                                                        ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
Available online at http://jddtonline.info 
REVIEW ARTICLE 
A MULTIPURPOSE AND NOVEL CARRIER FOR DRUG DELIVERY AND TARGETING - 
VIROSOMES 
Kapoor D*, Vyas RB, Lad C, Patel M 
Dr. Dayaram Patel Pharmacy College, Sardarbaug, Station Road, Bardoli, Dist – Surat, Gujarat, India, Pin-394601 
*Corresponding Author’sE-mail id – dev7200@gmail.com, Contact Info - +91-7874223242 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
A virosome is the reconstituted membrane of an enveloped 
virus. Many viruses are delimited by a membrane, or 
shroud, that is resulting from a membrane of the swarm 
cell; these viruses are produced by budding from a host 
cell membrane.  The envelope thus contains lipids of the 
host cell and viral proteins. These viral proteins have a 
purpose in binding to new host cells, and in inducing 
fusion of a membrane of the new host cell with the viral 
membrane. 
Virosomes are reconstituted viral envelopes that can make 
available as vaccines and as vehicles for cellular delivery 
of macromolecules. The panorama of drug delivery and 
targeting using virosomes is anfascinatingmeadow of 
research and development. Influenza virus is the most 
common virus of choice. The triumph of virosomal drug 
delivery depends on the methods used to prepare the 
encapsulated bioactive materials and integrate them into 
the virosomes, as are depiction and formulation of the 
finished preparation. Virosome technology could 
potentially be used to deliver peptides, nucleic acids or 
genes, and drugs like antibiotics, anticancer agents, and 
steroids. Reconstituted influenza virus envelopes 
(virosomes) containing the viral hemagglutinin (HA) have 
attracted consideration as liberation vesicles for cytosolic 
drug delivery as they acquire membrane fusion 
bustle.
1
Virosomes were first primed by Almeida et al., 
who inserted purified influenza spike proteins into 
preformed liposomes.
2
Enveloped creature viruses can send 
their genome into the cytoplasm of a host cell by fusing 
with the plasma membrane or with the endosomal 
membrane. 
3 
Virosome technology is a tool for developing novel, 
predominantly synthetic vaccines against infectious and 
chronic diseases. A virosome is a virus-like particle that 
acts as a vaccine carrier and adjuvant (immunity 
enhancing) system. Vaccines based on virosome 
technology combine high efficacy with high purity, which 
means they are effective and safe to use even in infants and 
individuals with a weakened immune system. A, rabies, 
tick-borne encephalitis, Japanese B encephalitis and Rift 
Valley fever 
4
. The difficulty in eliciting mucosal 
immunity with subunit vaccines has directed research in 
the development of new delivery systems which have 
improved local and systemic immune responses to mucosal 
administered antigens 
5,6,7,8
 
Benefits of Virosomal Drug Delivery 
Virosomes protect pharmaceutically active substances 
from proteolytic degradation and low pH within 
endosomes, allowing their contents to remain intact when 
they reach the cytoplasm. This is a major advantage of 
virosomal carrier systems over other drug-delivery 
vehicles, including liposomal and proteoliposomal carrier 
systems.Capable drugs are habitually discontinued for the 
duration ofenhancementfor the reason that they cannot be 
appropriately delivered to target cells, tissues, and organs. 
The new cohort of therapeutics alongside cancer or 
neurodegenerative disorders requires delivery systems that 
target drugs to precise cell types and host tissues by 
receptor-mediated uptake and controlled release. 
Virosomal technology presents a novel sophisticated 
delivery system to meet these challenges. 
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Virosomal technology is accepted by the FDA for bring 
into play in humans, and has a high security silhouette. 
Virosomes are biodegradable, biocompatible, and non-
toxic, no disease-transmission risk, no autoimmunogenity 
or anaphylaxis.Virosomes represent an innovative, broadly 
applicable carrier systemwith various prospective 
applications for the treatment and prevention ofcancer, 
neurodegenerative disorders and infectious diseases. 
Various pharmaceutically active substances like 
antibiotics, cytostatics, nucleic acids, fungicidesand 
antigens can be encapsulated into the virosomal carrier. 
Even thesurface of virosomes can be readily modified. The 
use of immune potentiatingreconstituted influenza 
virosomes (IRIV) 
9,10
broadly applicable with almost all 
important drugs (anticancer drugs, proteins, peptides, 
nucleic acids, antibiotics, fungicides). It enables drug 
delivery into the cytoplasm of target cell, promotes fusion 
activity in the endolysosomal pathway and protects drugs 
against degradation.  
Dissimilarityas of Liposomes: 
Liposomes have been measuredhopeful vehicles for 
targeting and liberation of biologically active molecules to 
living cells in cooperation in vitro and in vivo. However,  
liposomes have modestimpending to fuse with cells and 
thus, generally fail to make availablesubstantialrelease of 
encapsulated molecules to the cell cytoplasm. In disparity,  
virosomesrestrainserviceable viral envelope glycoproteins 
with receptor-binding and membrane-fusion properties 
that facilitate the cellular delivery of encapsulated 
molecules.
11
 
Imperviousretort: 
Virosomessymbolizeanpioneering drug-delivery system 
for an assortment ofpurely active molecules, but 
principally nucleic acids or genes, and for numerous 
indications. Influenza virosomes are virus-like particles, 
which hang on to the cell fastening and membrane fusion 
properties of the inhabitant virus, but lack the viral genetic 
substance. Theseserviceabledistinctiveness of influenza 
virosomesoutward appearance the foundation for their 
immunogenicity. Foremost, the rhythmic arrangement of 
the major viral packet glycoprotein, haemagglutinin, on the 
virosomalsurfacemediates a co-operative interaction with 
Ig receptors on B lymphocytes, invigorating strong 
antibody responses. The envelope proteins (thepeplomers) 
of enveloped viruses are the components that are important 
for induction of protective immunity 
12
. The opportunity of 
synthesizing hefty amounts of any preferred protein in 
bacteria, yeast or animal cells by means of recombinant 
DNA technology, subunit vaccines are attracting renewed 
interest 
13
. For enveloped viruses the spike glycoproteins 
are the antigens accountable forstimulating 
shieldingimmunity . Spike glycoproteins are amphiphilic 
proteins in which at least one subunit of the oligomeric 
protein is inserted into the lipid bilayer of the viral 
envelope and anchors the spike protein to the membrane 
14
. 
To fabricate a subunit vaccine containing only spike 
proteins, the proteins have to be secluded from the virus 
and freed from other virus components
15
. 
Preparation of virosomes: 
Virosomes made from influenza virus retain the cell entry 
and membrane fusion capacity of this virus 
16,17
. 
Functionally reconstituted influenza virosomes will bind to 
sialic acid residues on the surface of cells and enter the cell 
via receptormediated endocytosis 
18, 19
. Upon endocytosis, 
the low pH in the endosomes induces fusion of the 
virosomal membrane with the endosomal membrane, 
causing the release of the contents of the virosome into the 
cytoplasm of the cell. The fusion process is mediated by 
hemagglutinin, the major envelope glycoprotein of 
influenza virus 
20, 21
.These procedures involved in the 
insertion of influenza HA and NA into immunostimulating 
complexes (ISCOMS) 
22, 23
, plain liposomes, liposomes 
containing immunomodulators such as 
muramyldipeptide
24, 25
, or liposomes containing cationic 
lipids 
26.
 
Immunopotentiating reconstituted influenza virosomes 
(IRIVs) are prepared by the detergent removal of influenza 
surface glycoproteins, hemagglutinin (HA) and 
neuraminidase (NA), which are subsequently combined 
with natural and synthetic phospholipids. The 
phospholipids consist of 70% lecithin, a structural 
component, 20% cephalin, a structural component that also 
stimulates B cells independently of T-cell determinants 
and can bind hepatitis A antigen, and 10% envelope 
phospholipids, originating from the selected influenza 
virus. The resulting IRIVs are spherical, unilamellar 
vesicles with a mean diameter of approximately 150 nm 
and, due to the low viral and avian protein content, are a 
virtually non-immunogenic delivery system.  
Preparation of virosomes for drug delivery: 
To plan virosomes, a viral membrane-fusion protein such 
as HA—the generally preferred fusion protein for 
virosomes—is either purified from the analogous virus or 
fashioned recombinantly. The triumph of virosomes as a 
vaccine or delivery vehicle requires that reconstituted 
membrane proteins keep hold of their immunogenic 
properties as well as their receptor-binding and membrane-
fusion activities. This involves purposeful reconstitution of 
influenza virus membranes, which is based on solubilizing 
viral membranes by nondenaturing detergents. Influenza 
virus envelopes incorporated with HA can be solubilized 
with nonionic detergents having a relatively low critical 
micellar concentration (CMC). Octaethylene glycol mono 
(n-dodecyl) ether (C12E8) is the most commonly used 
detergent. Triton X-100 is a frequently used alternative 
detergent. Other nonionic detergents also can be used.
27
 
 
Figure 1: Reconstituted Influenza virosomes 
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Figure 2: Different components of virosome 
 
Figure 3: Different stages of preparation of 
Inflenzavirosomes (a-f) 
The perception of conferring viral functions to liposomes 
will show the way to ainnovativeground in drug delivery 
originalvirosome vectors will acquire the properties of 
competent delivery consequential from viral molecules and 
of lessened toxicity derived from liposomes. In recent 
times, a new approach, constructing influenza virosomes 
with a cationic lipid was reported. Influenza virus A was 
solubilized with detergent and assorted with a cationic 
lipid, dioleoyldimethylamonium chloride (DODAC), at 
30% to form a cationic virosomes. Plasmid DNA was 
complexed with these cationic virosomes and was 
fruitfully transferred to cultured cells by low pH-dependent 
membrane fusion.
28
 
Pellet is resuspended and left overnight to allow for 
complete solublisation of viral membrane. The suspension 
is homogenized and ultra centrifuged to pellet down viral 
nucleocapsids Proteins are added to the supernatant upon 
detergent extraction using biobeads the virosomes areform 
Virosomes suspension is purified by ultracentrifugation 
method. The virosomes can be dialyzed against buffer and 
sterilized by filtration. 
Mode of action: 
Virosomes operate both as a carrier and as an adjuvant, 
with multiple functions for the duration of initiation of an 
immune response. The carrier function comprises the 
affirmative effects of embedding the antigen into a 
privileged structure, the virosome particle. The adjuvant 
task relates to immune stimulating properties of the 
virosomes and their components on the immune system. 
Most importantly, virosomes accomplish something in 
stimulating specific immunity without causing nonspecific 
inflammation. 
Carrier 
function: 
The integration of the antigen into the higher structure of 
the virosome particle stabilizes the antigen, preserves the 
native status of B cell epitopes, and protects the antigen 
from degradation. The antigen displayed on the virosomal 
surface mimics the original pathogen or target cell and 
thereby favors the generation of antibodies relevant for 
protection. Moreover, the presentation of the antigen as a 
repetitive surface structure enhances its recognition by 
antibody-producing B cells. Finally, the size and surface 
structure of the virosome particles make them an attractive 
target for uptake and processing by immune cells, which is 
a crucial step in the initiation of an immune response. 
 
Figure 4: Mechanism of action: antibody response 
Evaluation parameters of Virosomes: 
1. Structure and size:  
Negative-stain electron microscopy can generally be used 
to determine the ultrastructure and size of virosomes. The 
staining solutions ought to preferably be of neutral pH, to 
avoid acid-induced conformational changes of HA.
29
 
2. Fusion activity:  
Generally virosomesdemonstrate pH-dependent membrane 
fusion activity analogous to native influenza virus.  
Virosomal fusion with biological or artificial intention 
membranes can be visualized with a fluorescent resonance 
energy transfer assay (RET).
30
 Instead, fusion can be 
assessed in vitro with an excimer assay using pyrene-
labeled lipids, where the dwindle of surface density of the 
pyrene-phosphatidylcholine-label on fusion with an 
unlabeled membrane corresponds to a diminution of 
excimer fluorescence.
29
Fusion activity also can be 
indirectly monitored by determining hemolytic activity,  
which corresponds intimately to fusion activity and 
exhibits a pH dependence identical with that of fusion. 
3. Protein detection:  
Virosome preparation should generally conclusion in a 
relativelystandardized protein-to-lipid proportion. Sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) can substantiate the pervasiveness of HA protein 
in the virosomes.
30
 
Specific delivery of nucleic acids/ genes: 
Bioactive drug compounds can be entrapped in the 
aqueous interior of the virosome or in the lipid membrane 
of the virosome for facilitated entry of the compounds into 
the cells.
31
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Virosomes are particularly useful for delivering nucleic acids 
or genes. These compounds are delivered into the host cell 
cytoplasm on fusion of the virosome with the endosome or 
plasma membrane.
20
 Nucleic acids or genes encoding a 
naturally occurring protein can be introduced into host cells 
and can be expressed, provided that the expression cassette 
contains the proper cis-acting regulatory elements.
32,33
 
Drugs or nucleic acids can be incorporated into the virosome 
at the time of virosome preparation. The bioactive compound 
is typically added to the lipid–HA-containing solution 
following removal of the nucleocapsid. Alternatively, the 
bioactive compound is initially incorporated into a liposome, 
which is then fused with a virosome containing two 
hemagglutinins with different pH thresholds to form a 
virosome–liposome hybrid.
34
 
Targeted delivery of proteins: 
Proteins also can be delivered to cells via virosome. For 
example, the gelonin subunit A of diphtheria toxin and 
ovalbumin have also been effectively delivered by virosome 
to target cells.
34,35
Virosomes carrying peptides consequential 
from the influenza nucleoprotein or intact ovalbumin induced 
strong cytotoxic T lymphocyte responses, which suggests that 
the encapsulated peptides and proteins gained access to the 
cytoplasm.
36,37
 
Carrier for antigen delivery: 
The potential for virosomes as delivery systems for peptide 
and nucleic acid based vaccines has been investigated for 
several diseases including malaria, melanoma, hepatitis C 
virus and Alzheimer’s disease
38
. When virosomes are to be 
used for the delivery of antigen into the cytosol of cells, 
fusion activity of the virosomes is of major significance. 
Studies have shown that virosomes as a delivery system are 
apposite for the resourceful induction of antibody responses 
against conformational epitopes by use of cyclic-template 
bound peptidomimetics. Virosomes as antigen carriers both 
defend the incorporated peptide and adjuvants and make 
available additional immunogenicity. By virtue of the fact that 
reconstituted viral envelopes closely mimic the outer surface 
of the virus they are derived from, virosomes also symbolize a 
very useful system for the initiation of antibody responses 
against the native virus 
39
. Furthermore, virosomes may also 
be used to integrate other unrelated antigens in the virosomal 
membrane. 
Conclusion: 
The challenge of novel vaccine development remains to 
design vaccine formulations that closely mimic a specific 
pathogen without being pathogenic themselves. The 
generation of reconstituted virus envelopes is a promising step 
in this direction. Virosomes derived from influenza virus can 
interact with the immune system in variousways eventually 
leading to activation of Bcells, dendritic cells and T cells as 
observed during virus infection 
40
. Virosomesretain the 
functional capacity of the original virus to bind to and enter 
cells andto fuse with limiting of the endosomal cell 
compartment such that the virosomecontent is delivered to the 
cytosol. This capacity opens the possibility todeliver antigens 
to the cytosol of antigen-presenting cells. These antigens can 
beprocessed and presented by MHC class I molecules to 
CD8+ T lymphocytesthus extending theimmuneresponse 
elicited. In the context of improved influenzavaccines, CTL 
activity directed against the major internal antigens of 
thevirus, NP and M1, may be induced in this manner. Finally, 
virosomes representan excellent platform for inclusion of 
specific lipophilic or amphiphatic adjuvantsfor further 
improvement of the quality and quantity of the 
inducedimmune response 
47
. With the new possibilities for 
mass production of virus antigens, theinterest in subunit 
vaccines has increased tremendously. There is no doubt 
thatwe have entered a new era in the development of 
vaccines. It will now bepossible to engineer viral antigens 
such that they will evoke an efficient immuneresponse with a 
maximum of safety. However, careful work is still needed 
toestablish the optimal way of presenting the relevant 
antigenic determinants tothe immune system of the host to 
induce humoral or mucosal immunity. Moreover,virosomes 
may also improve transfection efficiency by increasing 
theretention time and reducing the rate of DNA degradation 
by extracellular nucleases
41, 42
.Thus, the virosomes appear to 
be an effective tool for targeting andgene delivery, and they 
provide a novel promising approach for the developmentof 
efficious human vaccines. On the basis of their flexibility and 
stability,simple production and distinctive immunogenic 
properties, VLPs offer vastopportunities of application in the 
fields of vaccine development, gene therapyas well as 
nanobiotechnology
9
. Many lessons have been learned from 
VLPbasedtechnologies, which will certainly find themselves 
confronted by newchallenges in the near future, such as the 
demand for innovative biomaterials orpotent vaccines for 
newly emerging diseases 
43
. In this light it appears 
almostironical that viruses as such may serve a good purpose 
in the biotechnologicalera exploiting their weapons to beat 
them at their own game. 
Future prospects: 
Ideally one would like to be capable to target drug delivery to 
preferred tissues. One can adaptvirosomes to targets by 
incorporating precise molecules (e.g., Fab fragments and 
ligands) into the virosome'smasterpiece. The achievability of 
targeted delivery of anticancer drugs by means of virosomal 
carrier has been confirmed recently by two independent 
approaches. In one, a MAb cross-linked to the surface of 
virosomes mediated specific targeting of the virosomal carrier 
containing an anticancer drug (e.g., doxorubicin) to human 
cancer cells. MAbs can attachin particular to cancer-related 
antigens, provided that a means to target systemically 
administered virosomes to cancerous tissues. on the other 
hand, ligands that bind surface receptors on the target cells 
also can be hop to the virosomes to achieve targeted drug 
delivery. Tumors of mice treated with targeted drug-loaded 
virosomes failed to grow, and mortality of these animals was 
significantly reduced. These positive results will definitely 
open a new field of applications for virosomal technology.
29,31
 
Virosomes represent an innovative drug-delivery system for 
various biologically active molecules, but chiefly nucleic 
acids or genes, and for numerous indications. The surface of 
virosomes can be rightfully modified to make easy targeted 
drug delivery. However, their wide-ranging pharmacokinetic 
profile, bioavailability, clinical effects, and stability should be 
premeditated thoroughly to ascertain their long-term 
reliability as a safe, effective, and reasonable means for drug 
delivery and targeting. 
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